A first-in-human (FIH), multicentre, open-label, Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of YH004 as a single agent and YH004 in combination with Toripalimab (Anti-PD-1 mAb) in subjects with advanced solid tumors and relapsed or refractory non-hodgkin lymphoma